<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021589</url>
  </required_header>
  <id_info>
    <org_study_id>Microbio-WLS001</org_study_id>
    <nct_id>NCT04021589</nct_id>
  </id_info>
  <brief_title>Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer</brief_title>
  <official_title>A Study of Chemotherapy With WeiLeShu Versus Chemotherapy Alone in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 50 patients with metastatic colorectal cancer will be enrolled in the study. The
      patients were randomly divided into the WLS-intervention group and the control group. The two
      groups of patients were given the most appropriate medication according to the specific
      conditions of the disease. Patients in the intervention group received additional oral
      administration of Weileshu, a probiotics product (Tongchuang Biotechnology).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">July 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to approximately half a year</time_frame>
    <description>time from randomization to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to approximately two years</time_frame>
    <description>time from randomization to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Microbial Colonization</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>WLS-intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy + WLS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Weileshu</intervention_name>
    <description>a probiotics products which help to rebuild homeostasis of gut microbiome</description>
    <arm_group_label>WLS-intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>WLS-intervention group</arm_group_label>
    <arm_group_label>the control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age, of any race or sex who are eligible to sign written consent
             and have undergone prior resection of histological evidence of colorectal cancer

          -  Hematologic function: ANC ≥ 1.5 x 10 /L, platelets ≥ 75 x 10 /L, and hemoglobin &gt; 9
             g/dL Adequate liver function as measured by: total bilirubin ≤ 2.0 mg/dl, AST and ALT
             ≤ 5 ULN, albumin ≥ 2.5 g/dl Adequate renal function as measured by: creatinine ≤ 2.9
             mg/dl, &gt; 50 ml/min calculated by the C-G equation Non-pregnant women of childbearing
             potential and fertile men are required to use effective contraception (negative
             pregnancy test for women of child-bearing age) ECOG status ≤ 1 at screening

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijia Fang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weijia Fang, Doctor</last_name>
    <phone>+86 13758211655</phone>
    <email>dr.weijiafang@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijia fang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Weijia fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang, MD</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

